Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025

– Rademikibart demonstrated rapid and significant improvement in lung function and asthma control in patients, with greatest improvements observed in those with elevated baseline levels of key type 2 inflammatory markers –

Read more at globenewswire.com